Kyverna Therapeutics

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company’s work centers on engineered T-cell therapies, including CAR T-cell and related cell therapy approaches designed to target the immune cells that drive severe autoimmune and inflammatory conditions. Its current programs span multiple therapeutic areas, with particular emphasis on rheumatology and neurology, alongside research efforts in other antibody-mediated and inflammatory diseases. Kyverna Therapeutics develops product candidates for conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, stiff person syndrome, multiple sclerosis, and inflammatory bowel disease. The company’s platform combines advanced cell engineering and synthetic biology to pursue more precise immune modulation than traditional broad immunosuppressive treatments. Headquartered in Emeryville, California, Kyverna Therapeutics plays a specialized role in the biotechnology market by advancing cell-based immunology therapies for serious unmet medical needs.